1-甲基-2-吡啶-2-基肼 | 89875-95-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 1-甲基-2-吡啶-2-基肼
• 英文名称: N-methyl-N'-[2]pyridyl hydrazine
• 英文别名: N-Methyl-N'-[2]pyridyl-hydrazin；Nα-methyl-2-pyridylhydrazine；N-Methyl-N'-pyridyl-(2)-hydrazin；2-(2-Methylhydrazinyl)pyridine；1-methyl-2-pyridin-2-ylhydrazine
• CAS: 89875-95-6
• 化学式: C₆H₉N₃
• 分子量: 123.158
• InChiKey: RLWWJSJUMBUDQW-UHFFFAOYSA-N

物化性质

• 熔点：
  46 °C(Solv: ligroine (8032-32-4))
• 沸点：
  134-136 °C(Press: 12 Torr)
• 密度：
  1.08±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  37
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-氯吡啶 、 甲基肼 在 sodium hydroxide 作用下， 以 乙二醇甲醚 为溶剂， 生成 1-甲基-2-吡啶-2-基肼
  参考文献：
  名称：

  Photochromic compound and articles containing the same

  摘要：

  描述了螺合苯并噁嗪吡啶化合物。还描述了将这些化合物用作有机基体材料中的光致变色物质，例如有机透明塑料材料，例如眼镜镜片，以赋予其光致变色响应。

  公开号：

  US04986934A1

文献信息

• [EN] HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE TRANSPORT NUCLÉAIRE CONTENANT DE L'HYDRAZIDE ET LEURS UTILISATIONS
  申请人：KARYOPHARM THERAPEUTICS INC

  公开号：WO2013019548A1

  公开（公告）日：2013-02-07

  The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.

  这项发明通常与核运输调节剂有关，例如CRM1抑制剂，更具体地涉及一种由结构式(I)表示的化合物，或其药学上可接受的盐，其中变量的值和备选值如本文所定义和描述。该发明还包括合成和使用结构式I的化合物，或其药学上可接受的盐或组合物，例如在与CRM1活性相关的生理状况的治疗、调节和/或预防中的应用。
• [EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
  申请人：PHARMACIA CORP

  公开号：WO2004058762A1

  公开（公告）日：2004-07-15

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶2（MK-2）的化合物。描述了使用这些化合物来抑制MK-2，以及预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制剂化合物。还描述了包含本MK-2抑制剂化合物的治疗组合物、药物组合物和试剂盒。
• Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
  申请人：Pharmacia Corporation

  公开号：US20040209897A1

  公开（公告）日：2004-10-21

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2（MK-2）的化合物。本文还描述了使用这些化合物来抑制MK-2并预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制化合物。本文还描述了包含本MK-2抑制化合物的治疗组合物、制药组合物和试剂盒。
• Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity
  申请人：Moritani Yasunori

  公开号：US20090048256A1

  公开（公告）日：2009-02-19

  The present invention relates to a pyrazole compound having potent CB1-antagonizing activity, having the following formula [I]: wherein R 1 and R 2 are the same or different and an optionally substituted aryl group etc., R 3 is an alkyl group etc., E is one of the following groups of the formula (i) to (iv): Q 1 is a single bond, an alkylene group or a group of the formula: —N(R 7 )—, R 7 is a hydrogen atom or an alkyl group, Q 2 is a single bond, an oxygen atom or an alkylene group, R 4 is a cycloalkyl group, a group of the formula: —N(R 5 )(R 6 ) etc., one of R 5 and R 6 is a hydrogen atom or an alkyl group and the other is an alkyl group, a group of the formula: —N(R 8 )(R 9 ) etc., D is an oxygen atom etc., R A1 is an amino group etc., R A2 is an optionally substituted aliphatic heterocyclic group, R is an alkyl group optionally substituted by one to three halogen atom(s) etc., one of R 8 and R 9 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., or a pharmaceutically acceptable salt thereof.

  本发明涉及一种具有强效CB1拮抗活性的吡唑化合物，具有以下式[I]：其中R1和R2相同或不同，且可以是取代的芳基等，R3是烷基等，E是以下式(i)至(iv)中的一种基团：Q1是单键，烷基或式：—N（R7）—的基团，R7是氢原子或烷基，Q2是单键，氧原子或烷基，R4是环烷基，式：—N（R5）（R6）等的基团，其中R5和R6中的一个是氢原子或烷基，另一个是烷基，式：—N（R8）（R9）等的基团，D是氧原子等，RA1是氨基等，RA2是可选取代的脂肪族杂环基团，R是烷基，可选取代为1至3个卤原子等，R8和R9中的一个是氢原子或烷基，另一个是烷基等，或其药学上可接受的盐。
• PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS
  申请人：Aldous Suzanne C.

  公开号：US20100048568A1

  公开（公告）日：2010-02-25

  This invention is directed to a compound of formula (I): wherein R 1 , R 2 , R 3 , R 4 and L 1 are as defined herein, a pharmaceutical composition comprising the compound, and the use of the compound to treat allergic and/or inflammatory disorders, particularly disorders such as allergic rhinitis, asthma and/or chronic obstructive pulmonary disease (COPD).

  本发明涉及一种式(I)的化合物：其中R1、R2、R3、R4和L1如本文所定义，以及包含该化合物的药物组合物，以及使用该化合物治疗过敏和/或炎症性疾病，特别是过敏性鼻炎、哮喘和/或慢性阻塞性肺疾病（COPD）等疾病的用途。